Skip to content

The Effect of 5-hydroxytryptophan on ADHD Traits and Eye Movements

The Effect of 5-hydroxytryptophan on Microsaccades and Distractibility in Individual With High Levels of ADHD Traits: a Randomised, Double-blind Trial

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07777328
Enrollment
150
Registered
2026-08-20
Start date
2025-11-25
Completion date
2027-06-01
Last updated
2026-08-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Attention Deficit and Hyperactivity Disorder (ADHD), Attention Deficit Hyperactivity Disorder in Adults, Attention Deficits

Keywords

5-Hydroxytryptophan, Serotonin, ADHD, microsaccades, eye tracking, attention

Brief summary

The aim of this project is to look at the impact of 5-Hydroxytryptophan (5-HTP) on distractibility. 5-HTP is the precursor to the neurotransmitter serotonin and is a chemical that the body produces naturally. There is evidence that distractibility is associated with a decreased level of serotonin. This research aims to see if giving people 5-HTP will alter their distractibility, which will form part of an initial assessment as to whether 5-HTP could be used to support people with attention problems. The study involves completing a short survey about mental health and behaviours, and if eligible, participation in an in-person study at the University of Sheffield. The in-person session involves completing some cognitive tasks to look at eye movement, taking 5-HTP or a sugar tablet with no active ingredients, and then completing the tasks again after a 90-minute wait.

Detailed description

The overarching aim of this project is to assess the efficacy and suitability of 5-hydroxytryptophan, a nutritional supplement and precursor to serotonin, as a potential therapeutic for ADHD traits. 5-hydroxytryptophan is a metabolic product produced in the body following consumption of foods with high levels of the amino acid tryptophan, found in soy products, egg whites, and other high-protein foods. Both tryptophan and 5-hydroxytryptophan are metabolic precursors to serotonin, a neurotransmitter that is essential for the regulation of sleep, emotional state, aggression, and, most relevantly, the regulation of attention. Serotonin levels have been shown to be significantly reduced in individuals with ADHD, and some theories suggest that this is linked to reduced serotonin synthesis; of particular interest is the step where tryptophan is converted to 5-hydroxytryptophan, both the rate-limiting step of serotonin synthesis and a possible genetic locus of change in ADHD. 5-hydroxytryptophan can be readily obtained from health shops as a supplement, derived from the seeds of the edible plant Griffonia Simplicifolia, which has been long used in traditional medicine, and its ability to be absorbed easily from the intestinal tract and skip the rate-limiting step of synthesis makes it an attractive possible therapeutic. Pre-clinical work where 5-hydroxytryptophan was administered to Rhesus Macaques found that the supplement increased attention in animals with a low baseline level of attention, highlighting a possible benefit to supplementation. Although theoretically promising, our previous empirical study failed to find any effect of 5-hydroxytryptophan supplementation on individuals with high or low levels of ADHD-like traits. The study had several limitations, a significant one being that tasks that were meant to assess distractibility did not show a distractor effect, and did not provide discrimination between high and low ADHD trait groups. As such, we aim to attempt to re-assess the impact of 5-hydroxytryptophan with tasks that are better established as being ADHD-sensitive, particularly those of microsaccades and ocular motor behaviour, alongside a distractor task established in a previous pilot. Our primary study design also only considered one dose of 5-hydroxytryptophan, whereas in this iteration, we will use two different doses of 5-hydroxytryptophan to better establish a dose-response effect. Finally, given the heterogeneity of ADHD-traits and comorbidity with other neurodevelopmental and psychiatric conditions, we intend to better characterise the affective state of the cohort in order to better control for confounds and co-morbidity in the final data set. The proposed study will be conducted in two parts: A pre-screen survey to determine participant eligibility: AIM = to assess the eligibility and ADHD traits of potential participants. In-person participation in a randomised, double-blind trial at the University of Sheffield, where participants will ingest either intervention or placebo and complete cognitive tasks pre- and post-administration. AIM = to determine the impact of 5-hydroxytryptophan supplementation on cognitive and oculomotor behaviour of individuals with high and low levels of ADHD traits.

Interventions

DIETARY_SUPPLEMENT5-hydroxytryptophan (food supplement) 200mg

200mg 5-HTP delivered in two tablets. Tablets obtained from Nature's Best supplements. Each tablet contains 3982mg of Griffonia seed extract, providing 100mg of 5-HTP. The tablets consist of calcium carbonate, griffonia seed extract, Anti-caking Agents (Silicon Dioxide, Stearic Acid, \& Magnesium Stearate) and Tablet Coating (Hydroxypropyl Methylcellulose, Glycerol).

DIETARY_SUPPLEMENT5-hydroxytryptophan (food supplement) 300mg

300mg 5-HTP delivered in three tablets. Tablets obtained from Nature's Best supplements. Each tablet contains 3982mg of Griffonia seed extract, providing 100mg of 5-HTP. The tablets consist of calcium carbonate, griffonia seed extract, Anti-caking Agents (Silicon Dioxide, Stearic Acid, \& Magnesium Stearate) and Tablet Coating (Hydroxypropyl Methylcellulose, Glycerol).

OTHERPlacebo

Unmedicated lactose-sucrose tablets provided by Ainsworth's homoeopathic remedies

Sponsors

University of Sheffield
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
Yes

Inclusion criteria

* 18-65 years of age * Normal or corrected to normal vision with contact lenses. * Score of \<9 or \>14 on the ASRS v5 (assessed in pre screen questionnaire)

Exclusion criteria

* Current use of psychostimulant medication or medication for the treatment of ADHD * Current use of medications known to impact the serotonergic system (e.g., SSRIs). * Smoking or vaping * Pregnancy * Breast feeding * Lactose intolerance * Veganism * Dyslexia

Design outcomes

Primary

MeasureTime frameDescription
Change in distractibility - microsaccadespre and 90 minutes post administrationFrequency of microsaccades in a simple fixation task
Change in distractibility - reaction timepre and 90 minutes post administrationMeasurement of reaction time on a visual search task with varying auditory stimuli.
Change in distractibility- fixationspre and 90 minute post administrationNumber of fixations on distractor letters in a visual search task with varying auditory stimuli.

Countries

United Kingdom

Contacts

CONTACTEleanor F Jackson
efjackson1@sheffield.ac.uk+447908873415
CONTACTPaul G Overton, Professor
p.g.overton@sheffield.ac.uk

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Aug 21, 2026